Browse

Clinical results of stereotactic body frame based fractionated radiation therapy for primary or metastatic thoracic tumors

DC Field Value Language
dc.contributor.authorYoon, Sang Min-
dc.contributor.authorChoi, Eun Kyung-
dc.contributor.authorLee, Sang-Wook-
dc.contributor.authorYi, Byong Yong-
dc.contributor.authorAhn, Seung Do-
dc.contributor.authorShin, Seong Soo-
dc.contributor.authorPark, Heon Joo-
dc.contributor.authorKim, Su Ssan-
dc.contributor.authorPark, Jin-Hong-
dc.contributor.authorSong, Si Yeol-
dc.contributor.authorPark, Charn Il-
dc.contributor.authorKim, Jong Hoon-
dc.date.accessioned2010-01-08T08:28:25Z-
dc.date.available2010-01-08T08:28:25Z-
dc.date.issued2006-11-23-
dc.identifier.citationActa Oncol. 2006;45(8):1108-14.en
dc.identifier.issn0284-186X (Print)-
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17118847-
dc.identifier.urihttps://hdl.handle.net/10371/29072-
dc.description.abstractThe aim of this study was to evaluate the treatment outcomes of stereotactic body radiation therapy for treating primary or metastatic thoracic tumors using a stereotactic body frame. Between January 1998 and February 2004, 101 lesions from 91 patients with thoracic tumors were prospectively reviewed. A dose of 10-12 Gy per fraction was given three to four times over consecutive days to a total dose of 30-48 Gy (median 40 Gy). The overall response rate was 82%, with 20 (22%) complete responses and 55 (60%) partial responses. The one- and two-year local progression free survival rates were 90% and 81%, respectively. The patients who received 48 Gy showed a better local tumor control than those who received less than 48 Gy (Fisher exact test; p = 0.004). No pulmonary complications greater than a RTOG toxicity criteria grade 2 were observed. The experience of stereotactic body frame based radiation therapy appears to be a safe and promising treatment modality for the local management of primary or metastatic lung tumors. The optimal total dose, fractionation schedule and treatment volume need to be determined after a further follow-up of these results.en
dc.language.isoen-
dc.publisherTaylor & Francisen
dc.subjectAdolescenten
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAged, 80 and overen
dc.subjectChilden
dc.subjectDose Fractionationen
dc.subjectFemaleen
dc.subjectHumansen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectPositron-Emission Tomographyen
dc.subjectRadiosurgery/*instrumentationen
dc.subjectSurvival Rateen
dc.subjectThoracic Neoplasms/*surgeryen
dc.subjectTreatment Outcomeen
dc.titleClinical results of stereotactic body frame based fractionated radiation therapy for primary or metastatic thoracic tumorsen
dc.typeArticleen
dc.contributor.AlternativeAuthor윤상민-
dc.contributor.AlternativeAuthor최은경-
dc.contributor.AlternativeAuthor이상욱-
dc.contributor.AlternativeAuthor이병용-
dc.contributor.AlternativeAuthor안승도-
dc.contributor.AlternativeAuthor신성수-
dc.contributor.AlternativeAuthor박헌주-
dc.contributor.AlternativeAuthor박진홍-
dc.contributor.AlternativeAuthor송시열-
dc.contributor.AlternativeAuthor박찬일-
dc.contributor.AlternativeAuthor김종훈-
dc.identifier.doi10.1080/02841860600812685-
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Radiation Oncology (방사선종양학전공)Journal Papers (저널논문_방사선종양학전공)
Files in This Item:
There are no files associated with this item.
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse